Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | SPHK1 | Q9NYA1 | 15/20 | 0.50 |
| ▸ | SPHK2 | Q9NRA0 | 12/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2733156 | 1.00 | HDAC8 (0.53) | HDAC8HDAC6HDAC1SPHK1SPHK2 | |
| SCHEMBL19994 | 1.00 | HDAC8 (0.53) | HDAC8HDAC6HDAC1SPHK1SPHK2 | |
| SCHEMBL30660 | 0.90 | HDAC8 (0.52) | HDAC8HDAC6HDAC1KCNH2CA12 | |
| SCHEMBL30653 | 0.82 | HDAC6 (0.45) | HDAC8HDAC6HDAC1KCNH2CA12 | |
| SCHEMBL30446 | 0.80 | HDAC1 (0.49) | HDAC8HDAC6HDAC1SPHK1KCNH2 | |
| SCHEMBL15235871 | 0.80 | HDAC6 (0.43) | HDAC8HDAC6HDAC1KCNH2 | |
| SCHEMBL28743 | 0.80 | HDAC6 (0.43) | HDAC8HDAC6HDAC1KCNH2 | |
| SCHEMBL29629 | 0.79 | HDAC1 (0.55) | HDAC8HDAC6HDAC1KCNH2 | |
| SCHEMBL29630 | 0.79 | HDAC1 (0.55) | HDAC8HDAC6HDAC1KCNH2 | |
| SCHEMBL29097 | 0.79 | HDAC1 (0.55) | HDAC8HDAC6HDAC1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231373-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | NOVARTIS AG (CH) | 2013-09-05 | — | — | US | disclosed |
| US-20110060009-A1 | Hydroxamate-Based Inhibitors of Deacetylases | NOVARTIS AG | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231373-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | HDAC1, HDAC11, HDAC3 | HDAC8 8/4885HDAC6 11/4885HDAC1 1/4885 |
| US-20110060009-A1 | Hydroxamate-Based Inhibitors of Deacetylases | HDAC1, HDAC11, HDAC3 | HDAC8 8/4885HDAC6 10/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.